Small molecule · developed by Novartis
Artemether and lumefantrine is a fixed-dose oral combination of two antimalarial agents, artemether and lumefantrine, in a 1:6 ratio. It is used to treat acute, uncomplicated Plasmodium falciparum malaria, including in patients with a body weight of 5 kg and above, and is studied in uncomplicated P. falciparum malaria.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Mar 26, 2026). Read the full label for the exact wording, limitations and safety information.
Uncomplicated Plasmodium Falciparum Malaria
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →